ArticleInternational journal of clinical and experimental pathology2025
Analysis of the correlation between COL11A1 gene expression and clinical features in bladder urothelial carcinoma.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder urothelial carcinoma (BLCA) is a prevalent urinary malignancy that complicates diagnosis and treatment. This study investigates the diagnostic and prognostic utility of COL11A1, a gene implicated in tumor progression and immune modulation, by analyzing its association with clinicopathological features, tumor progression, and immune infiltration dynamics. Using statistical methods, including Kaplan-Meier survival analysis and immune infiltration profiling, we evaluated COL11A1 expression in 407 BLCA patients and 28 normal controls. Results demonstrated significant COL11A1 overexpression in BLCA tissues versus controls (P < 0.001), with elevated expression correlating with poorer survival outcomes (hazard ratio = 1.53, P = 0.005). Immune infiltration analysis revealed robust positive associations between COL11A1 levels and macrophages, Th1 cells, natural killer (NK) cells, and neutrophils (P < 0.001), alongside significant links to advanced T stage (P < 0.001) and N stage (P = 0.030). These findings establish COL11A1 as a multifaceted biomarker for BLCA, offering critical insights into diagnosis, prognosis, and therapeutic strategies. Further research should elucidate its mechanistic roles in tumorigenesis and immune regulation, with potential applications across malignancies to advance personalized oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.